NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development

By January 2, 2018News

NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners. In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors.

View Original Article »

Join our Mailing List